Clinical Cancer Research Versailles No Abst Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 14, 1182, February 15, 2008. doi: 10.1158/1078-0432.CCR-07-1216
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Merchant, N. B.
Right arrow Articles by Coffey, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Merchant, N. B.
Right arrow Articles by Coffey, R. J.

Cancer Therapy: Preclinical

TACE/ADAM-17: A Component of the Epidermal Growth Factor Receptor Axis and a Promising Therapeutic Target in Colorectal Cancer

Nipun B. Merchant1, Igor Voskresensky1, Christopher M. Rogers1, Bonnie LaFleur2, Peter J. Dempsey7, Ramona Graves-Deal5, Frank Revetta4, A. Coe Foutch1, Mace L. Rothenberg3, Mary K. Washington4 and Robert J. Coffey3,5,6

Authors' Affiliations: 1 Surgery, 2 Biostatistics, 3 Medicine, 4 Pathology, and 5 Cell and Developmental Biology, Vanderbilt University Medical Center, 6 Nashville Veterans Affairs Medical Center, Nashville, Tennessee, and 7 Department of Pediatrics and Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan

Requests for reprints: Robert J. Coffey, Jr., Vanderbilt University Medical Center, 4140 MRB III, 465 21st Avenue South, Nashville, TN 37232-8355. Phone: 615-343-1590; Fax: 615-343-1591; E-mail: robert.coffey{at}vanderbilt.edu.

Purpose: Activation of the epidermal growth factor receptor (EGFR) requires cell surface cleavage of EGFR ligands, uptake of soluble ligand by the receptor, and initiation of EGFR tyrosine kinase activity. We define these collective events as the EGFR axis. Transforming growth factor-{alpha} (TGF-{alpha}) and amphiregulin are two EGFR ligands that are delivered preferentially to the basolateral surface of polarized epithelial cells where the EGFR resides. TACE/ADAM-17 (tumor necrosis factor-{alpha} converting enzyme/a disintegrin and metalloprotease) has been implicated in ectodomain cleavage of TGF-{alpha} and amphiregulin.

Experimental Design: Using a human polarizing colorectal cancer (CRC) cell line, HCA-7, and a tissue array of normal colonic mucosa and primary and metastatic CRC, we determined the intracellular localization of TACE and the effects of EGFR axis inhibition in CRC.

Results: Herein, we show that TACE is localized to the basolateral plasma membrane of polarized HCA-7 cells. TACE is overexpressed in primary and metastatic CRC tumors compared with normal colonic mucosa; the intensity of its immunoreactivity is inversely correlated with that of TGF-{alpha} and amphiregulin. Pharmacologic blockade of HCA-7 cells with an EGFR monoclonal antibody, a selective EGFR tyrosine kinase inhibitor, and a selective TACE inhibitor results in concentration-dependent decreases in cell proliferation and active, phosphorylated mitogen-activated protein kinase. Combining suboptimal concentrations of these agents results in cooperative growth inhibition, increased apoptosis, and reduced mitogen-activated protein kinase pathway activation. Furthermore, an EGFR tyrosine kinase–resistant clone of HCA-7 cells is growth-inhibited by combined monoclonal antibody and TACE inhibition.

Conclusion: These results implicate TACE as a promising target of EGFR axis inhibition in CRC.




This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
C. Berasain, M. J. Perugorria, M. U. Latasa, J. Castillo, S. Goni, M. Santamaria, J. Prieto, and M. A. Avila
The Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver Cancer
Experimental Biology and Medicine, July 1, 2009; 234(7): 713 - 725.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Horiuchi, T. Kimura, T. Miyamoto, K. Miyamoto, H. Akiyama, H. Takaishi, H. Morioka, T. Nakamura, Y. Okada, C. P. Blobel, et al.
Conditional Inactivation of TACE by a Sox9 Promoter Leads to Osteoporosis and Increased Granulopoiesis via Dysregulation of IL-17 and G-CSF
J. Immunol., February 15, 2009; 182(4): 2093 - 2101.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. J. Duffy, E. McKiernan, N. O'Donovan, and P. M. McGowan
Role of ADAMs in Cancer Formation and Progression
Clin. Cancer Res., February 15, 2009; 15(4): 1140 - 1144.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.